目的:探讨甲泼尼龙联合阿奇霉素治疗儿童难治性肺炎支原体肺炎的有效性及安全性。方法:检索Pubmed、Embase、Cochrane Library、Web of Science、知网、中国生物文献数据库、万方、维普数据库,检索截止日期为数据库建库至2023年10月,筛选探讨甲泼尼龙联合阿奇霉素治疗儿童难治性肺炎支原体肺炎疗效及安全性的随机对照试验(RCT),选择符合纳排标准的文献进行Meta分析,使用RevMan 5.1软件处理数据。结果:本文最终纳入29篇文献,共计2538名患儿。Meta分析结果显示,联合使用甲泼尼龙和阿奇霉素较单用阿奇霉素能提高总有效率(RR = 1.24, 95%CI (1.19, 1.28), P MD = −2.88, 95%CI (−3.18, −2.57), P MD = −2.98, 95%CI (−3.49, −2.47), P MD = −4.15, 95%CI (−5.88, −2.42), P MD = −3.60, 95%CI (−4.58, −2.62), P MD = −15.35, 95%CI (−18.86, −11.84), P RR = 0.85, 95%CI (0.64, 1.12), P = 0.25 > 0.05)。结论:通过对现有文献的综合分析发现,甲泼尼龙联合阿奇霉素治疗儿童难治性肺炎支原体肺炎较单用阿奇霉素可以提高治疗有效性,且安全性良好。Objective: To explore the efficacy and safety of methylprednisolone combined with azithromycin in the treatment of refractory Mycoplasma pneumoniae pneumonia in children. Methods: PubMed, Embase, Cochrane Library, Web of Science, CNKI, CBM, Wanfang Database, and VIP Database were searched. The search time limit was built until October 2023. Randomized Controlled Trials (RCTs) of exploring the efficacy and safety of methylprednisolone combined with azithromycin in the treatment of children with refractory Mycoplasma pneumoniae pneumonia were included. Literature that met the criteria was selected for Meta-analysis, and RevMan 5.1 software was used to process the data. Results: 29 studies involving 2538 patients were finally included in this paper. Meta-analysis showed that the combination of methylprednisolone and azithromycin increased the overall efficacy rate compared wi
